CytoSorbents Corporation · NASDAQ:CTSO
CytoSorbents — BIO CEO & Investor Conference 2018
20 slides from CytoSorbents's conference presentation, Feb 13, 2018
Slide 1: BIO CEO & Investor Presentation
HELPING REDUCE DEADLY UNCONTROLLED INFLAMMATION IN HOSPITALIZED PATIENTS WORLDWIDE NASDAQ: CTSO BIO CEO & Investor Presentation February 13, 2018
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future re
Slide 3: CytoSorbents is A Leader in Critical Care Immunotherapy
CytoSorbents is A Leader in Critical Care Immunotherapy Leading the Prevention or Treatment of Life-Threatening Inflammation in the ICU and Cardiac Surgery using CytoSorb® Blood Purification 3
Slide 4: CytoSorbents At a Glance
CytoSorbents At a Glance • NASDAQ-traded (CTSO): ~$7.00 per share • CytoSorb®, is E.U. approved, with 35,000+ treatments; distributed in 44 countries • Pre-announced total 2017 revenue of $15M+, including full year CytoSorb sales of $13.2M, with $17.3M in cash at year-end 2017 • ~90 employees with i
Slide 5: Uncontrolled Inflammation is Deadly
Uncontrolled Inflammation is Deadly Sepsis Trauma Influenza Burn Injury Millions Die Of Uncontrolled Deadly Inflammation Each Year Lung Injury Cytokine Release Syndrome Pancreatitis Liver Failure Surgical Complications 5
Slide 6: Massive Inflammation Causes Organ Failure
Massive Inflammation Causes Organ Failure Organ failure occurs when vital organs stop working, causing nearly half of all deaths in the ICU. Little can be done to prevent or treat organ failure today 6
Slide 7: No Ideal Options to Treat Severe Inflammation
No Ideal Options to Treat Severe Inflammation Anti-Inflammatory Immunosuppressive (too weak) (too strong) NSAIDs Corticosteroids Aspirin Chemotherapy Organ transplant Anti-cytokine Anti-rejection drugs antibodies Radiation Anti-integrin antibodies Immune system ablation Anti-oxidants Anti-leukocyte
Slide 8: CytoSorb Reduces the Fuel to the Fire
CytoSorb® Reduces the Fuel to the Fire • CytoSorb® targets the $20+ billion opportunity in critical care and cardiac surgery • Approved in the European Union as the only specifically approved extracorporeal cytokine adsorber • Broad indication for use where cytokines are elevated • Removes cytokines
Slide 9: Patented Blood Purification Technology
Patented Blood Purification Technology The underlying blood purification technology is based on biocompatible, highly porous polymer beads that act like tiny sponges to remove harmful substances from blood Each bead is about the size of a grain of salt . • Proprietary patented technology with multip
Slide 10: CytoSorb is "Plug and Play"
CytoSorb is “Plug and Play” Compatible with Existing Dialysis and Heart-Lung Machines Place a temporary dialysis catheter in a major vein Connect the device to a standard dialysis, ECMO, or heart-lung machine found in hospitals worldwide Pump blood out of the body and through the cartridge T
Slide 11: Goal: To Prevent or Treat Organ Failure
Goal: To Prevent or Treat Organ Failure Improve Decrease Patient Costs Of Outcome ICU and and Patient Survival Care Sepsis ARDS Burn Injury Trauma Pancreatitis Influenza Surgical The Potential to Revolutionize Critical Care Medicine 11
Slide 12: Refractory Septic Shock
Refractory Septic Shock Prospective, single arm study in 20 patients with refractory late-stage septic shock using CytoSorb aggressively every 12 hours with a new cartridge • Patients had refractory shock despite high doses of vasopressors, respiratory failure requiring mechanical ventilation, oligo
Slide 13: Seasonal Influenza
Seasonal Influenza • Seasonal influenza in the US (CDC data) • Current 2017-18 US epidemic is particularly severe • Poor vaccine coverage, virulent H3N2 strain, widespread • In addition to very young and elderly, otherwise healthy people are dying from influenza • Cytokine storm, severe inflammation
Slide 14: Case Report: Influenza
Case Report: Influenza 56 year old man with documented swine (H1N1) influenza with multiple organ failure. Interferon levels were undetectable Treatment day 1 2 3 4 5 6 7 IL-6 (before) 8,076 1,025 527 172 117 120 107 pg/mL IL-6 (after) pg/mL 2,621 663 289 76 110 111 94 IL-6 (% change) -68% -35% -45%
Slide 15: CAR-T Cell Immunotherapy and CRS
CAR-T Cell Immunotherapy and CRS • CAR-T cell cancer immunotherapy is one of the most promising treatments for blood cancers. However, ~40-50% of patients develop cytokine release syndrome (CRS), a cytokine storm that can lead to rapid organ failure and death • CytoSorb® was specifically designed to
Slide 16: REFRESH 2 - AKI Targets US Approval
REFRESH 2 - AKI Targets US Approval REFRESH 2 – AKI is a pivotal, multi-center RCT using CytoSorb intraoperatively to reduce the incidence or severity of acute kidney injury (AKI) in high risk cardiac surgery patients • The development of even mild AKI after surgery predicts 1 and 5 year mortality a
Slide 17: Quarterly Product Sales
Quarterly Product Sales $4,500,000 $4,200,000 CytoSorb® Product Sales $4,000,000 $3,448,661 $3,500,000 $3,041,012 $3,000,000 $2,596,133 $2,612,801 $2,500,000 $2,143,116 $1,852,670 $2,000,000 $1,597,449 $1,495,590 $1,500,000 $1,031,761 $1,071,459 $871,150 $773,112 $1,000,000 $663,233 $703,658 $569,24
Slide 18: Historical Annual Product Sales
Historical Annual Product Sales Over the past three years, the compound growth rate of return (“CAGR”) on product sales was 62% $14,000,000 $13,200,000 CytoSorb® Product Sales $12,000,000 $10,000,000 $8,206,036 $8,000,000 Trend Line $6,000,000 $4,043,819 $4,000,000 $3,135,387 $2,000,000 $821,787 $-
Slide 19: Expected 2018 Investor Catalysts
Expected 2018 Investor Catalysts • Ongoing rapid sales growth and gross margin expansion • Quarterly operating profitability in 2018* • Potential new and/or expansion of existing strategic partnerships • Continued execution of pivotal REFRESH 2 study • Publications of key clinical and research data
Slide 20: NASDAQ: CTSO Dr. Phillip Chan, MD, PhD – CEO pchan@cytosorbents.com
NASDAQ: CTSO Dr. Phillip Chan, MD, PhD – CEO pchan@cytosorbents.com